×
Regencell Bioscience Holdings Price to Free Cash Flow Ratio 2020-2023 | RGC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Regencell Bioscience Holdings price to free cash flow ratio from 2020 to 2023. Price to free cash flow ratio can be defined as
View More
Regencell Bioscience Holdings Price to Free Cash Flow Ratio 2020-2023 | RGC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Regencell Bioscience Holdings price to free cash flow ratio from 2020 to 2023. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$160.6B
Vertex Pharmaceuticals (VRTX)
$126.2B
Bristol Myers Squibb (BMY)
$119.7B
Gilead Sciences (GILD)
$117.5B
Regeneron Pharmaceuticals (REGN)
$90.2B
CSL (CSLLY)
$90B
GSK (GSK)
$73.6B
Argenex SE (ARGX)
$35.5B
Alnylam Pharmaceuticals (ALNY)
$34.7B
BioNTech SE (BNTX)
$25.5B
Biogen (BIIB)
$24.5B
Illumina (ILMN)
$23.4B
BeiGene (BGNE)
$18.9B
Moderna (MRNA)
$16.7B
Incyte (INCY)
$15.5B
Genmab (GMAB)
$14.9B
BioMarin Pharmaceutical (BMRN)
$12.6B
Insmed (INSM)
$12.5B
Vaxcyte (PCVX)
$12.4B
Bio-Techne Corp (TECH)
$11.8B
Sarepta Therapeutics (SRPT)
$10.9B
Exelixis (EXEL)
$10.2B
Revolution Medicines (RVMD)
$10B
QIAGEN (QGEN)
$9.9B
Intra-Cellular Therapies (ITCI)
$9.4B
Bio-Rad Laboratories (BIO.B)
$9.4B
Exact Sciences (EXAS)
$9.3B
Roivant Sciences (ROIV)
$8.6B
Repligen (RGEN)
$8.3B
Ascendis Pharma (ASND)
$7.7B